基于结构的设计小分子抑制剂的人类介质素-6的结构
bioRxiv : the preprint server for biology
|January 7, 2025
概括
研究人员确定了一种小分子抑制剂,该抑制剂显著降低了人类中白素-6 (hIL-6) 的活性,这是炎症的关键驱动因素. 这一发现为开发针对hIL-6相关疾病的向疗法提供了一个有希望的新途径.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 人类介质素-6 (hIL-6) 是一种促炎性细胞因子,与许多疾病有关.
- 目前的治疗包括针对hIL-6或其受体 (IL-6Rα) 的单克隆抗体.
- 需要采用替代治疗策略,例如小分子抑制剂.
研究的目的:
- 确定hIL-6的新型小分子对手.
- 为了利用基于结构的计算选用于药物发现.
- 通过体外测试验证潜在的抑制剂.
主要方法:
- 使用集体对接的基于高吞吐量结构的计算选.
- 对阿波hIL-6蛋白质的分子动力学模拟.
- 在体外功能测试以测试对IL6诱导的STAT3记者活性的抑制作用.
主要成果:
- 计算选确定了得分最高的小分子连接体.
- 一种化合物显著抑制了IL6诱导的STAT3活性 (∼84%).
- 这种化合物在中显示出第二高的计算结合亲和力.
结论:
- 这项研究成功地发现了一种强大的小分子抑制剂hIL-6.
- 这一发现支持开发用于hIL-6介导疾病的基于小分子的治疗方法.
- 这种已识别的化合物代表了未来药物设计的有希望的线索.
相关概念视频
The JAK-STAT Signaling Pathway
8.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.3K
Protein-protein Interfaces
12.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.4K


